SNDX Stock Forecast: Syndax Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.72
−4.55% on the day

The median 12-month analyst price target for Syndax Pharmaceuticals, Inc. is $31. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 58 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$785.0M
Ticker Nerd rank
58/ 100
Median analyst target
$31
Analysts covering
12
Revenue$72.8M+91.8% y/y
Operating income−$40.0M
Net income−$49.4M
Free cash flow−$30.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.8%
1M
−34.2%
YTD
−58.5%
1Y
−48.9%
From 52W high
−65.3%
From 52W low
+1.8%
$9
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Syndax Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
58/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Value
93
Quality
82
Volatility
77
Momentum
43
Revisions
34
Accruals
29
Issuance
12

Growth (94): Sales and profits are climbing, and climbing faster than before.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SNDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26SNDXHigh $57Median $31Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12
Buy
0
Hold
0
Sell
$17
Low
$31
Median
$57
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
3 Nov 2026HC Wainwright & Co.MaintainsBuy$38 → $36
13 Oct 2026HC Wainwright & Co.ReiteratesBuy$38
21 Aug 2026UBSMaintainsBuy$37 → $33
11 Aug 2026JP MorganMaintainsOverweight$44 → $40
5 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $38
15 July 2026HC Wainwright & Co.ReiteratesBuy$40
12 June 2026HC Wainwright & Co.ReiteratesBuy$40
22 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026UBSMaintainsBuy—
1 May 2026BarclaysMaintainsOverweight—
1 Apr 2026Goldman SachsMaintainsBuy—
31 Mar 2026MizuhoMaintainsOutperform—
30 Mar 2026JefferiesAssumesBuy$48 → $40
9 Mar 2026JP MorganMaintainsOverweight—
2 Mar 2026CitigroupMaintainsBuy—
27 Jan 2026MizuhoMaintainsOutperform$410 → $600
9 Dec 2025BTIGReiteratesBuy—
24 Nov 2025BarclaysMaintainsOverweight—
12 Nov 2025JP MorganMaintainsOverweight—
4 Nov 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SNDX.

Market Radar

This page is one stock. Monday covers all of them.

SNDX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SNDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Syndax Pharmaceuticals, Inc. returned −48.9% against +6.9% for the S&P 500, dividends included.

SNDX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26SNDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SNDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.7×

Cheaper than 40% of US stocks

Price / book
51.4×

Cheaper than 1% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
95.6%

Higher than 98% of US stocks

Operating margin
−61.7%

Higher than 17% of US stocks

Net margin
—
Returns & dividend
Return on equity
−426.4%

Higher than 3% of US stocks

Return on assets
−17.9%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Syndax Pharmaceuticals, Inc. has a market value of $785.0M and an enterprise value of $937.2M.

  • Revenue in the twelve months to 30 June 2026: $252.3M. The latest quarter grew 91.8% year on year.

  • Net income over the same four quarters: −$220.8M, a −87.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.51.

  • Free cash flow in the twelve months to 30 June 2026: −$220.9M.

  • Shares outstanding: 89.2M.

  • Syndax Pharmaceuticals, Inc. employs 298 people — $846K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

SNDX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SNDXSyndax Pharmaceuticals, Inc.$785.0M58
ORICOric Pharmaceuticals, Inc.$761.9M53
ARDXArdelyx, Inc.$751.6M57
VSTMVerastem, Inc.$769.1M39
RIGLRigel Pharmaceuticals, Inc.$741.7M84
OBXObsidian Therapeutics, Inc.$740.7M36
MTRIMentari Therapeutics, Inc.$776.4M24

Take a look at SNDX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Syndax Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SNDX

What is the SNDX stock price forecast for 2026-2027?

The median 12-month analyst price target for Syndax Pharmaceuticals, Inc. is $31, with estimates ranging from $17 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SNDX stock a buy right now?

Of the 12 analysts covering Syndax Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Syndax Pharmaceuticals, Inc. 58 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SNDX?

As at 21 Nov 2026, Syndax Pharmaceuticals, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will SNDX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts is $31, and Ticker Nerd's factor model ranks Syndax Pharmaceuticals, Inc. 58 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SNDX stock forecast for 2030?

No analyst covering Syndax Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $57 over the next 12 months.

How has SNDX stock performed over the past year?

Syndax Pharmaceuticals, Inc. returned -48.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Syndax Pharmaceuticals, Inc. do?

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease.

Company

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its current portfolio centers on treatments for hematologic malignancies and serious immune-related conditions, with products that address acute leukemias and chronic graft-versus-host disease. The company’s work spans research, regulatory advancement, and commercial execution, combining clinical development with product launch and market support. Syndax Pharmaceuticals also collaborates with partners to broaden access to its therapies and strengthen its presence in oncology and related specialty care markets. Headquartered in New York, New York, Syndax Pharmaceuticals, Inc. plays a role in advancing targeted treatment options for patients with high unmet medical needs.

CEO Mr. Michael A. Metzger M.B.A. · 298 employees · United States · https://syndax.com